Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative GroupA Thyss, S Suciu, Y Bertrand, et al.Leukemia|September 19, 2014
MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemiaE Mets, J Van der Meulen, G Van Peer, et al.Leukemia|September 2, 2005
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportN Entz-Werle, S Suciu, J van der Werff ten Bosch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.Leukemia|June 9, 2015
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951E Clappier, N Grardel, M Bakkus, et al.Leukemia|September 26, 2013
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletionsE Clappier, M F Auclerc, J Rapion, et al.Leukemia|February 24, 2001
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative GroupE Vilmer, S Suciu, A Ferster, et al.Leukemia|December 25, 2009
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008M Brüggemann, A Schrauder, T Raff, et al.Ecancermedicalscience|January 26, 2012
The state of research into children with cancer across Europe: new policies for a new decadeK Pritchard-Jones, G Lewison, S Camporesi, et al.Leukemia|October 14, 2006
Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique HématologiqueB Cauwelier, H Cavé, C Gervais, et al.Pageof 9